tradingkey.logo

TG Therapeutics Inc <TGTX.OQ> expected to post earnings of 8 cents a share - Earnings Preview

ReutersFeb 28, 2025 2:12 PM
  • TG Therapeutics Inc TGTX.OQ TGTX.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024

  • The Morrisville North Carolina-based company is expected to report a 127.3% increase in revenue to $99.954 million from $43.97 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for TG Therapeutics Inc is for earnings of 8 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for TG Therapeutics Inc is $43.00​, above​ its last closing price of $28.53. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

0.04

0.03

0.02

Missed

-32.2

Jun. 30 2024

-0.05

-0.05

0.04

Beat

187.5

Mar. 31 2024

-0.02

-0.04

-0.07

Missed

-96​

Dec. 31 2023

-0.12

-0.10

-0.10

Met

4.1

​​Sep. 30 2023

0.05

0.12

0.73

Beat

530.9

Jun. 30 2023

-0.24

-0.25

-0.34

Missed

-36.7​

Mar. 31 2023

-0.38

-0.37

-0.28

Beat

23.7

Dec. 31 2022

-0.28

-0.26

-0.39

Missed

-50

This summary was machine generated February 28 at 14:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI